Adalimumab

Drug Profile

Adalimumab

Alternative Names: ABT-D2E7; D2E7; Humira; LU 200134; Raheara

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Cambridge Antibody Technology
  • Developer AbbVie; Eisai Co Ltd; Interstitial Cystitis Study
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hidradenitis suppurativa; Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis
  • Phase III Pustular psoriasis
  • Discontinued Interstitial cystitis

Most Recent Events

  • 30 Mar 2017 US FDA approves addition of Fingernail poriasis data to the prescribing information of adalimumab
  • 11 Mar 2017 AbbVie completes the phase III CLEAR trial in Plaque psoriasis (Combination therapy) in Canada (NCT02196701)
  • 17 Feb 2017 AbbVie has composition of matter patents for adalimumab in European Union and is expected to expire in October 2018 (AbbVie 10-K form, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top